Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 24 publications
FDA Approval Summary: Pembrolizumab, Atezolizumab, and Cemiplimab-rwlc as Single Agents for First-Line Treatment of Advanced/Metastatic PD-L1-High NSCLC.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: October 26, 2021
Recommendations for Dose Selection for Adolescent Patients in Relevant Adult Oncology Clinical Trials.
Journal: Clinical pharmacology and therapeutics
Published: July 29, 2021
FDA Approval Summary: Nivolumab Plus Ipilimumab for the Treatment of Patients with Hepatocellular Carcinoma Previously Treated with Sorafenib.
Journal: The oncologist
Published: January 19, 2021
Advancing Assessment, Analysis, and Reporting of Safety and Tolerability in Cancer Trials.
Journal: Journal of the National Cancer Institute
Published: August 19, 2020
Reducing Uninformative IND Safety Reports: A List of Serious Adverse Events anticipated to Occur in Patients with Lung Cancer.
Journal: Therapeutic innovation & regulatory science
Published: December 28, 2019
Assessing an ASCO Decision Aid for Improving the Accuracy and Attribution of Serious Adverse Event Reporting From Investigators to Sponsors.
Journal: Journal of oncology practice
Published: October 25, 2019
A phase 1 study of cabozantinib in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1211, a report from the Children's Oncology Group.
Journal: Pediatric blood & cancer
Published: October 10, 2017
Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysis.
Journal: The Lancet. Oncology
Published: September 14, 2017
Challenges in Opening and Enrolling Patients in Clinical Trials.
Journal: American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
Published: June 01, 2017
Last Updated: 09/26/2026